ReShape Lifesciences (NASDAQ:RSLS), Inc. (NASDAQ: RSLS) is a medical device company dedicated to developing and commercializing minimally invasive solutions for obesity and metabolic health. The company’s flagship product, the ReShape Dual Balloon System, is an endoscopically delivered intragastric device designed to promote weight loss through gastric volume displacement. By offering a non-surgical alternative to traditional bariatric procedures, ReShape aims to address a growing global demand for less-invasive interventions in the management of obesity and related comorbidities.
Founded in 2010 and headquartered in San Clemente, California, ReShape Lifesciences has expanded its presence through regulatory approvals and strategic partnerships. The ReShape Dual Balloon System has received clearance from the U.S. Food and Drug Administration, as well as CE Mark certification in Europe. These clearances have enabled the company to establish a commercial footprint in key markets across North America and Europe, and to position its products for broader adoption by physicians and integrated healthcare networks.
In addition to its core intragastric balloon technology, the company invests in ongoing research and development to enhance device performance and patient outcomes. This commitment extends to clinical studies focused on optimizing treatment protocols and exploring adjunctive therapies. ReShape’s product pipeline reflects a strategy of innovation in endoscopic and minimally invasive solutions, with the goal of delivering safe, effective, and scalable options for patients battling obesity.
Under the leadership of its CEO and President, Michael R. Marinaro, and supported by a management team with deep expertise in medical technology commercialization, ReShape Lifesciences continues to pursue growth opportunities and collaborative ventures. The company’s board of directors comprises industry veterans who guide strategic planning, regulatory affairs, and market expansion initiatives. Together, they aim to position ReShape as a trusted partner in the global fight against obesity, driving long-term value through clinical efficacy and patient-centric care.
